Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Operating Leases: 2019-2024

Historic Operating Leases for Viking Therapeutics (VKTX) over the last 5 years, with Dec 2024 value amounting to $630,000.

  • Viking Therapeutics' Operating Leases fell 57.88% to $318,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $318,000, marking a year-over-year decrease of 57.88%. This contributed to the annual value of $630,000 for FY2024, which is 32.69% down from last year.
  • Viking Therapeutics' Operating Leases amounted to $630,000 in FY2024, which was down 32.69% from $936,000 recorded in FY2023.
  • Over the past 5 years, Viking Therapeutics' Operating Leases peaked at $1.3 million during FY2022, and registered a low of $29,000 during FY2020.
  • Moreover, its 3-year median value for Operating Leases was $936,000 (2023), whereas its average is $942,000.
  • Data for Viking Therapeutics' Operating Leases shows a maximum YoY crashed of 91.94% (in 2020) over the last 5 years.
  • Over the past 4 years, Viking Therapeutics' Operating Leases (Yearly) stood at $29,000 in 2020, then reached $1.3 million in 2022, then dropped by 25.71% to $936,000 in 2023, then slumped by 32.69% to $630,000 in 2024.